Sponsored by
Associated Press
04.13.2005, 09:47 AM
Vion Pharmaceuticals Inc., a cancer drug developer, said Wednesday that a group of hospitals specializing in treating children's brain tumors has begun an early-stage clinical study of its cancer-fighting drug, Cloretazine.
The Pediatric Brain Tumor Consortium - comprising leading academic and children's hospitals around the country - will conduct the study, which will gauge the effects of Cloretazine in children with recurrent, progressive or refractory primary brain tumors, the company said.
Vion said its drug aims to circumvent drug resistance in tumors, the usual cause of treatment failure in children with recurrent malignant brain tumors.
The company's shares fell 7 cents, or 2.6 percent, to $2.60 in morning trading on the Nasdaq.